Talk to the Veterans Crisis Line now
U.S. flag
An official website of the United States government

VA Health Systems Research

Go to the VA ORD website
Go to the QUERI website

HSR&D Citation Abstract

Search | Search by Center | Search by Source | Keywords in Title

Association between ß-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension.

Stefan MS, Rothberg MB, Priya A, Pekow PS, Au DH, Lindenauer PK. Association between ß-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. Thorax. 2012 Nov 1; 67(11):977-84.

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.
   Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions



Abstract:

BACKGROUND: -Blocker therapy has been shown to improve survival among patients with ischaemic heart disease (IHD) and congestive heart failure (CHF) and is underused among patients with chronic obstructive pulmonary disease (COPD). Evidence regarding the optimal use of -blocker therapy during an acute exacerbation of COPD is particularly weak. METHODS: We conducted a retrospective cohort study of patients aged 40 years with IHD, CHF or hypertension who were hospitalised for an acute exacerbation of COPD from 1 January 2006 to 1 December 2007 at 404 acute care hospitals throughout the USA. We examined the association between -blocker therapy and in-hospital mortality, initiation of mechanical ventilation after day 2 of hospitalisation, 30-day all-cause readmission and length of stay. RESULTS: Of 35 082 patients who met the inclusion criteria, 29% were treated with blockers in the first two hospital days, including 22% with 1-selective and 7% with non-selective blockers. In a propensity-matched analysis, there was no association between -blocker therapy and in-hospital mortality (OR 0.88, 95% CI 0.71 to 1.09), 30-day readmission (OR 0.96, 95% CI 0.89 to 1.03) or late mechanical ventilation (OR 0.98, 95% CI 0.77 to 1.24). However, when compared with 1 selective blockers, receipt of non-selective blockers was associated with an increased risk of 30-day readmission (OR 1.25, 95% CI 1.08 to 1.44). CONCLUSIONS: Among patients with IHD, CHF or hypertension, continuing 1-selective blockers during hospitalisation for COPD appears to be safe. Until additional evidence becomes available, 1-selective blockers may be superior to treatment with a non-selective blocker.





Questions about the HSR website? Email the Web Team

Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.